^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    GENE:

    CXCL10 (Chemokine (C-X-C motif) ligand 10)

    i
    Other names: CXCL10, C7, crg-2, gIP-10, IFI10, INP10, IP-10, mob-1, SCYB10, Chemokine (C-X-C motif) ligand 10
    1d
    Oxycodone induces HMGB1-mediated neuroimmune crosstalk between oligodendrocytes and microglia. (PubMed, Neuroscience)
    Collectively, we show OLs as an unrecognized source of HMGB1 during oxycodone exposure and establish a novel OL-microglia signaling axis underlying neuroinflammation. These insights emphasize the importance of glial crosstalk in opioid-related pathologies and may inform therapeutic strategies targeting HMGB1 signaling.
    Journal
    |
    IL6 (Interleukin 6) • CXCL10 (Chemokine (C-X-C motif) ligand 10) • HMGB1 (High Mobility Group Box 1) • TLR4 (Toll Like Receptor 4) • IL1B (Interleukin 1, beta) • TLR2 (Toll Like Receptor 2)
    3d
    Cytosolic DNA structures produced by mismatch repair deficiency coordinate anti-tumor immunity in colorectal cancer. (PubMed, Cell Rep)
    We also show that micronuclei are less effective at inducing anti-tumor immunity and instead increase Treg activation and IL-10 production. Overall, these data highlight the role of specific cyDNA structures in anti-tumor immunity and provide knowledge for improved design of therapeutic DNA-based cGAS/STING agonists to improve the prognosis of poorly immunogenic tumors like CIN CRCs.
    Journal • Mismatch repair
    |
    CD8 (cluster of differentiation 8) • CXCL10 (Chemokine (C-X-C motif) ligand 10) • IL10 (Interleukin 10)
    4d
    UNC93B1 promotes pancreatic cancer progression through modulation of cGAS-STING signaling. (PubMed, Front Immunol)
    The strong correlation between UNC93B1 overexpression and adverse clinical outcomes underscores its potential as a dual diagnostic biomarker and therapeutic target. This work not only provides a mechanistic foundation for novel precision immunotherapies in PDAC but also establishes a robust methodological paradigm for multi-omics-driven discovery in oncology.
    Journal • IO biomarker
    |
    CDKN2A (Cyclin Dependent Kinase Inhibitor 2A) • CDH1 (Cadherin 1) • CXCL10 (Chemokine (C-X-C motif) ligand 10) • IFNB1 (Interferon Beta 1) • UNC93B1 (Unc-93 Homolog B1)
    5d
    Relevance of Chemokines in Mobilizing γδ T Cells in the Biliary Tract Cancer Microenvironment: Potential for γδ T-Cell-Based Adoptive Cell Therapy. (PubMed, Am J Clin Oncol)
    Comprehensive single-cell analysis identified selective chemokine recruitment signatures supporting γδ T-cell infiltration but revealed paradoxical corecruitment of immunosuppressive populations. Patient stratification through chemokine profiling, combined with γδ T-cell enrichment and targeted chemokine antagonism, represents a rational therapeutic strategy.
    Journal
    |
    CXCR4 (Chemokine (C-X-C motif) receptor 4) • IFNG (Interferon, gamma) • CXCL8 (Chemokine (C-X-C motif) ligand 8) • CXCL10 (Chemokine (C-X-C motif) ligand 10) • CXCL12 (C-X-C Motif Chemokine Ligand 12) • CXCL9 (Chemokine (C-X-C motif) ligand 9) • CCL5 (Chemokine (C-C motif) ligand 5) • CCL4 (Chemokine (C-C motif) ligand 4) • CCL2 (Chemokine (C-C motif) ligand 2) • CCL3 (C-C Motif Chemokine Ligand 3) • CCR2 (C-C Motif Chemokine Receptor 2) • CXCR1 (Chemokine (C-X-C motif) receptor 1) • CXCR6 (C-X-C Motif Chemokine Receptor 6) • CXCL16 (C-X-C Motif Chemokine Ligand 16)
    8d
    Identification of Novel Hub Genes and Potential Signaling Pathways with the Pathogenesis of Oral Cavity Squamous Cell Carcinoma Based on Bioinformatics Analysis. (PubMed, Cancer Inform)
    It was revealed that the development and prediction of OSCC may be affected by hsa-mir-146a-5 and hsa-mir-155-5p. Novel potential biomarkers and signaling pathways associated with OSCC have been identified, which may be important in the transformation of OSCC adenocarcinoma and may serve as therapeutic targets for OSCC.
    Journal • IO biomarker
    |
    CXCL8 (Chemokine (C-X-C motif) ligand 8) • CXCL10 (Chemokine (C-X-C motif) ligand 10) • MIR155 (MicroRNA 155) • STAT1 (Signal Transducer And Activator Of Transcription 1) • IL1B (Interleukin 1, beta) • TLR2 (Toll Like Receptor 2)
    8d
    The promise of IL-1β modulation in NSCLC clinical context. (PubMed, Front Immunol)
    These findings contrast sharply with the failure of multiple CANOPY trials targeting IL-1β, suggesting that blockade may be effective only in prevention or early carcinogenesis. Instead, controlled IL-1β activation, guided by biomarkers and combined with chemotherapy plus PD-1 blockade, may represent a promising strategy to overcome resistance in established NSCLC.
    Journal • PD(L)-1 Biomarker • IO biomarker
    |
    CD8 (cluster of differentiation 8) • CXCL10 (Chemokine (C-X-C motif) ligand 10) • IL1B (Interleukin 1, beta)
    11d
    Urinary Chemokines in the Diagnosis and Monitoring of Immune Checkpoint Inhibitor-Associated Nephritis. (PubMed, Int J Mol Sci)
    The decrease of CXCL9 and CXCL10 correlated with greater kidney function recovery at one-year follow-up. These molecules could serve as noninvasive biomarkers and may aid fine patient monitoring.
    Journal • Checkpoint inhibition • PD(L)-1 Biomarker • IO biomarker
    |
    PD-L1 (Programmed death ligand 1) • PD-1 (Programmed cell death 1) • IL6 (Interleukin 6) • CXCL10 (Chemokine (C-X-C motif) ligand 10) • PD-L2 (Programmed Cell Death 1 Ligand 2) • CXCL9 (Chemokine (C-X-C motif) ligand 9) • CXCL11 (C-X-C Motif Chemokine Ligand 11) • CCL2 (Chemokine (C-C motif) ligand 2) • CCL3 (C-C Motif Chemokine Ligand 3) • CXCL5 (Chemokine (C-X-C motif) ligand 5)
    12d
    EGFR and IRE1α pathways are associated with distinct immunomodulatory gene expression profiles in NSCLC cells with acquired resistance to EGFR TKIs. (PubMed, Arch Biochem Biophys)
    EGFR-TKI-resistant cell lines were established by long-term exposure to gefitinib, afatinib, and osimertinib via the PC9 model. Targeting endoplasmic reticulum (ER) stress pathways alongside immune checkpoint inhibitors may be crucial for overcoming resistance mechanisms identified here. These insights provide a rationale for personalized treatment strategies tailored to the immune-related gene-expression profiles observed in EGFR-TKI-resistant NSCLC models, aiming to enhance therapeutic responses and improve clinical outcomes.
    Preclinical • Journal • Gene Expression Profile • PD(L)-1 Biomarker • IO biomarker
    |
    IFNG (Interferon, gamma) • IL6 (Interleukin 6) • CXCL8 (Chemokine (C-X-C motif) ligand 8) • CXCL10 (Chemokine (C-X-C motif) ligand 10) • CCL2 (Chemokine (C-C motif) ligand 2) • CCL22 (C-C Motif Chemokine Ligand 22)
    |
    PD-L1 expression
    |
    Tagrisso (osimertinib) • Gilotrif (afatinib) • gefitinib • simmitinib (SYHA1817)
    14d
    β-Adrenergic Signaling Promotes Anti-Tumor Immunity in TP53-mutant Oral Squamous Cell Carcinoma. (PubMed, Adv Sci (Weinh))
    Notably, the CXCL10-driven T cell response is associated with simultaneous upregulation of both activation and exhaustion markers, indicating a robust but transient effector state within the tumor microenvironment. Collectively, these findings uncover a neuro-immune axis that reverses immune escape in p53-deficient HNSCC and suggest novel therapeutic strategies targeting adrenergic signaling to convert immune "cold" tumors into "hot" ones more amenable to immunotherapy.
    Journal • IO biomarker
    |
    TP53 (Tumor protein P53) • CD8 (cluster of differentiation 8) • CXCL10 (Chemokine (C-X-C motif) ligand 10) • CXCR3 (C-X-C Motif Chemokine Receptor 3)
    |
    TP53 mutation
    14d
    Gene Expression Profiling to Unveil Novel Biomarkers for Early Diagnosis and Therapies for Breast Cancer. (PubMed, Curr Top Med Chem)
    The stability of the top three receptor-ligand complexes was validated through molecular dynamics simulations. Therefore, our findings could be a valuable resource for researchers and medical professionals, aiding in BC diagnosis and treatment.
    Journal • BRCA Biomarker • PARP Biomarker
    |
    EGFR (Epidermal growth factor receptor) • TP53 (Tumor protein P53) • BRCA1 (Breast cancer 1, early onset) • CXCL10 (Chemokine (C-X-C motif) ligand 10) • STAT3 (Signal Transducer And Activator Of Transcription 3) • CAV1 (Caveolin 1) • MIR155 (MicroRNA 155) • CD34 (CD34 molecule) • CXCL12 (C-X-C Motif Chemokine Ligand 12) • CD36 (thrombospondin receptor) • PTGS2 (Prostaglandin-Endoperoxide Synthase 2) • CD31 (Platelet and endothelial cell adhesion molecule 1) • MIR16 (MicroRNA 16) • MIR23b (MicroRNA 23b) • PECAM1 (Platelet And Endothelial Cell Adhesion Molecule 1) • PACERR (PTGS2 Antisense NFKB1 Complex-Mediated Expression Regulator RNA)
    |
    Lynparza (olaparib) • lapatinib • Verzenio (abemaciclib) • Tukysa (tucatinib)
    16d
    RT-ICI therapy induces a distal immunometabolic axis that shapes systemic macrophage polarization and enhances local T cell immunity. (PubMed, Cell Commun Signal)
    Ligand-receptor analysis and pseudotime modeling revealed that irradiated tumor cells acted as "in situ vaccines" by enhancing MHC-TCR interactions and promoting T cell differentiation along non-exhausted cytotoxic lineages. Together, these findings reveal a dual mechanism by which RT-ICI therapy enhances local anti-tumor immunity while modulating systemic lipid metabolism and macrophage polarization, offering insights for combinatorial immunotherapy design in immunologically "cold" tumors.
    Journal • PD(L)-1 Biomarker • IO biomarker
    |
    CXCL10 (Chemokine (C-X-C motif) ligand 10) • GZMB (Granzyme B)
    18d
    Latent Neoehrlichia mikurensis Infections May Be Reactivated in Patients With B-Cell Lymphomas Treated With Rituximab. (PubMed, Immunology)
    The infected lymphoma patients also had expanded γδ T-cell populations. This study supports the notion of latent, reactivatable N. mikurensis infections.
    Journal
    |
    CD8 (cluster of differentiation 8) • IFNG (Interferon, gamma) • CXCL10 (Chemokine (C-X-C motif) ligand 10) • PRF1 (Perforin 1)
    |
    Rituxan (rituximab)